Christopher Bell1, Nicholas Dowson2, Simon Puttick3, Yaniv Gal4, Paul Thomas5, Mike Fay6, Jye Smith7, Stephen Rose8. 1. CSIRO Preventative Health Flagship, CSIRO Computational Informatics, The Australian e-Health Research Centre, Herston QLD 4029, Australia; The University of Queensland, School of Medicine, St. Lucia QLD 4072, Australia. 2. CSIRO Preventative Health Flagship, CSIRO Computational Informatics, The Australian e-Health Research Centre, Herston QLD 4029, Australia. 3. Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia QLD 4072, Australia. 4. The University of Queensland, Centre for Medical Diagnostic Technologies in Queensland, St. Lucia QLD 4072, Australia. 5. Department of Radiation Oncology, Royal Brisbane and Women's Hospital, Herston QLD 4029, Australia. 6. The University of Queensland, School of Medicine, St. Lucia QLD 4072, Australia; Genesis Cancer Care, Lake Macquarie Private Hospital, 36 Pacific Highway, Gateshead NSW 2290, Australia; Specialised PET Services Queensland, Royal Brisbane and Women's Hospital, Herston QLD 4029, Australia. 7. The University of Queensland, School of Medicine, St. Lucia QLD 4072, Australia; Specialised PET Services Queensland, Royal Brisbane and Women's Hospital, Herston QLD 4029, Australia. 8. CSIRO Preventative Health Flagship, CSIRO Computational Informatics, The Australian e-Health Research Centre, Herston QLD 4029, Australia. Electronic address: Stephen.Rose@csiro.au.
Abstract
INTRODUCTION: Despite radical treatment therapies, glioma continues to carry with it a uniformly poor prognosis. Patients diagnosed with WHO Grade IV glioma (glioblastomas; GBM) generally succumb within two years, even those with WHO Grade III anaplastic gliomas and WHO Grade II gliomas carry prognoses of 2-5 and 2 years, respectively. PET imaging with (18)F-FDOPA allows in vivo assessment of the metabolism of glioma relative to surrounding tissues. The high sensitivity of (18)F-DOPA imaging grants utility for a number of clinical applications. METHODS: A collection of published work about (18)F-FDOPA PET was made and a critical review was discussed and written. RESULTS: A number of research papers have been published demonstrating that in conjunction with MRI, (18)F-FDOPA PET provides greater sensitivity and specificity than these modalities in detection, grading, prognosis and validation of treatment success in both primary and recurrent gliomas. In further comparisons with (11)C-MET, (18)F-FLT, (18)F-FET and MRI, (18)F-FDOPA has shown similar or better efficacy. Recently synthesis cassettes have become available, making (18)F-FDOPA more accessible. CONCLUSIONS: According to the available data, (18)F-FDOPA PET is a viable radiotracer for imaging and treatment planning of gliomas. ADVANCES IN KNOWLEDGE AND IMPLICATION FOR PATIENT CARE: (18)F-FDOPA PET appears to be a viable radiopharmaceutical for the diagnosis and treatment planning of gliomas cases, improving on that of MRI and (18)F-FDG PET. Crown
INTRODUCTION: Despite radical treatment therapies, glioma continues to carry with it a uniformly poor prognosis. Patients diagnosed with WHO Grade IV glioma (glioblastomas; GBM) generally succumb within two years, even those with WHO Grade III anaplastic gliomas and WHO Grade II gliomas carry prognoses of 2-5 and 2 years, respectively. PET imaging with (18)F-FDOPA allows in vivo assessment of the metabolism of glioma relative to surrounding tissues. The high sensitivity of (18)F-DOPA imaging grants utility for a number of clinical applications. METHODS: A collection of published work about (18)F-FDOPA PET was made and a critical review was discussed and written. RESULTS: A number of research papers have been published demonstrating that in conjunction with MRI, (18)F-FDOPA PET provides greater sensitivity and specificity than these modalities in detection, grading, prognosis and validation of treatment success in both primary and recurrent gliomas. In further comparisons with (11)C-MET, (18)F-FLT, (18)F-FET and MRI, (18)F-FDOPA has shown similar or better efficacy. Recently synthesis cassettes have become available, making (18)F-FDOPA more accessible. CONCLUSIONS: According to the available data, (18)F-FDOPA PET is a viable radiotracer for imaging and treatment planning of gliomas. ADVANCES IN KNOWLEDGE AND IMPLICATION FOR PATIENT CARE: (18)F-FDOPA PET appears to be a viable radiopharmaceutical for the diagnosis and treatment planning of gliomas cases, improving on that of MRI and (18)F-FDG PET. Crown
Authors: Talia C Oughourlian; Jingwen Yao; Jacob Schlossman; Catalina Raymond; Matthew Ji; Hiroyuki Tatekawa; Noriko Salamon; Whitney B Pope; Johannes Czernin; Phioanh L Nghiemphu; Albert Lai; Timothy F Cloughesy; Benjamin M Ellingson Journal: J Neurooncol Date: 2020-01-24 Impact factor: 4.130
Authors: Maria C Rossi Espagnet; Andrea Romano; Valeria Mancuso; Francesco Cicone; Antonio Napolitano; Claudia Scaringi; Giuseppe Minniti; Alessandro Bozzao Journal: Br J Radiol Date: 2016-08-09 Impact factor: 3.039
Authors: Ryan S Youland; Deanna H Pafundi; Debra H Brinkmann; Val J Lowe; Jonathan M Morris; Bradley J Kemp; Christopher H Hunt; Caterina Giannini; Ian F Parney; Nadia N Laack Journal: J Neurooncol Date: 2018-01-13 Impact factor: 4.130
Authors: Manuel Röhrich; Anastasia Loktev; Annika K Wefers; Annette Altmann; Daniel Paech; Sebastian Adeberg; Paul Windisch; Thomas Hielscher; Paul Flechsig; Ralf Floca; Dominik Leitz; Julius P Schuster; Peter E Huber; Jürgen Debus; Andreas von Deimling; Thomas Lindner; Uwe Haberkorn Journal: Eur J Nucl Med Mol Imaging Date: 2019-08-06 Impact factor: 9.236
Authors: Robert Kosztyla; Srinivas Raman; Vitali Moiseenko; Stefan A Reinsberg; Brian Toyota; Alan Nichol Journal: Br J Radiol Date: 2019-05-14 Impact factor: 3.039
Authors: Michelle M Kim; Yilun Sun; Madhava P Aryal; Hemant A Parmar; Morand Piert; Benjamin Rosen; Charles S Mayo; James M Balter; Matthew Schipper; Nicolette Gabel; Emily M Briceño; Daekeun You; Jason Heth; Wajd Al-Holou; Yoshie Umemura; Denise Leung; Larry Junck; Daniel R Wahl; Theodore S Lawrence; Yue Cao Journal: Int J Radiat Oncol Biol Phys Date: 2021-01-29 Impact factor: 8.013
Authors: Katarina J Makaravage; Allen F Brooks; Andrew V Mossine; Melanie S Sanford; Peter J H Scott Journal: Org Lett Date: 2016-10-10 Impact factor: 6.005
Authors: David Sipos; Zoltan László; Zoltan Tóth; Peter Kovács; Jozsef Tollár; Akos Gulybán; Ferenc Lakosi; Imre Repa; Arpad Kovács Journal: Front Oncol Date: 2021-07-06 Impact factor: 6.244